Evidence map›Paper›PMID 38150586›Full record

ArticleBlood advances2024

Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.

Bradley Haverkos, Jasmine Zain, Manali Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Ajay Major, Steven Bair, Jagar Jasem, Clayton Smith and 2 more

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Bradley HaverkosDivision of Hematology, University of Colorado, Aurora, CO.ORCID 0000-0002-3872-0615
Jasmine ZainDivision of Hematology, City of Hope, Duarte, CA.ORCID 0000-0003-4308-629X
Manali KamdarDivision of Hematology, University of Colorado, Aurora, CO.
Alexander NeuweltDivision of Hematology and Oncology, Virginia Commonwealth University, Richmond, VA.
Eduardo DavilaDivision of Oncology, University of Colorado, Aurora, CO.ORCID 0000-0001-9738-4167
Xander BradeenDivision of Hematology, University of Colorado, Aurora, CO.ORCID 0000-0002-5731-2860
Ajay MajorDivision of Hematology, University of Colorado, Aurora, CO.
Steven BairDivision of Hematology, University of Colorado, Aurora, CO.
Jagar JasemDivision of Hematology, University of Colorado, Aurora, CO.
Clayton SmithDivision of Hematology, University of Colorado, Aurora, CO.
Diana AbbottDivision of Hematology, University of Colorado, Aurora, CO.
Pierluigi PorcuDivision of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA.ORCID 0000-0002-8056-023X
University of Colorado Anschutz Medical Campus · USCity of Hope · USThomas Jefferson University Hospital · USVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, T-Cell, PeripheralNivolumabHumansNivolumab

Identifiers

PMID38150586
PMCPMC10845026
OpenAlexW4390263755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.